Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK

This publication has 38 references indexed in Scilit:

• NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
  Cancer, 2023
• Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2022
• Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers
  ESMO Open, 2022
• ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up
  Radiotherapy and Oncology, 2015
• A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
  Gynecologic Oncology, 2014
• A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia
  Gynecologic Oncology, 2014
• A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
  Gynecologic Oncology, 2012
• A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia
  Gynecologic Oncology, 2010
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
  EMBO Molecular Medicine, 2009
• A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer
  International Journal of Clinical Oncology, 2008